A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
Key facts
- Who runs it
- Omnix Medical Ltd
- Where
- Greece, Hungary, Israel, and Italy21 sites in 4 countriesChoose a country to see its sites
- Trial code
- NCT06087536
- EU 2025-524200-29-00
- U1111-1331-9149
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 54 people, planned
- Started
- 14 May 2026
- Expected to end
- Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- OMN6
- Placebo
- Record updated
- 28 September 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- A signed informed consent form
- Male or female patients 18 years or older
- A diagnosis of either a HABP or a VABP
- ABC infection of the lower respiratory tract suspected based on a positive rapid testing of respiratory specimens
- Women of childbearing potential (WOCBP) (i.e., not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization
- Acute Physiology and Chronic Health Evaluation II (APACHE II) score between 10 and 24
Who cannot take part
- Acute respiratory distress syndrome
- Immunosuppressed patients (due to either immunosuppressant drugs or to any medical condition)
- History of any known hypersensitivity to colistin or to carbapenems
- Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
- Moderate to severe reduction of renal function
- Liver dysfunction
- Evidence of septic shock
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
This trial is currently available in Greece and Israel.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.
The 2 groups in the trial
- OMN6 treatmentTreatment being tested
OMN6 on top of Meropenem and Colistin
Treatment: OMN6
- PlaceboPlacebo, for comparison
Placebo on top of Meropenem and Colistin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
- Criteria questions
- Built from NCT06087536, who can take part
- Record updated
- 28 September 2026